Ultrasound Velocimetry in the Abdominal Aorta Before and After Endovascular Aneurysm Repair
NCT ID: NCT05148988
Last Updated: 2024-11-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
12 participants
OBSERVATIONAL
2022-07-06
2023-08-22
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Objective: The aim of this study is to determine the feasibility of ultrafast contrast-enhanced ultrasound particle image velocimetry (echoPIV) measurements to quantify spatiotemporal blood flow velocity profiles in the abdominal aorta of AAA patients before and after endovascular repair.
Secondary objectives are to determine the correlation between echoPIV and phase-contrast MRI (PC MRI) based measurements to ultimately validate the spatiotemporal velocity profiles obtained with echoPIV. Furthermore, changes in blood flow velocity profiles after placement of a stent graft will be evaluated.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
3D Ultrasound of Abdominal Aortic Aneurysm Characteristics
NCT05871515
Non Invasive Imaging of Abdominal Aorta Aneurysm Hemodynamics and Wall Structure
NCT01104688
Tonometry and Duplex Ultrasound to Predict AAA Progression and CV Events in Aneurysm Patients (1-2-3 Trial)
NCT03989011
Non-invasive Aortic Aneurysm Tissue Characterization Using Wall Viscoelasticity
NCT04150653
Vector Velocity Imaging in AAA Patients
NCT05841524
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AAA patients
The entire cohort consists of patients with an abdominal aortic aneurysm eligible for endovascular repair using an Endurant II device.
EchoPIV
All patients will undergo an echoPIV measurement 6 to 8 weeks before and 6 to 8 weeks after endovascular aneurysm repair. These measurements will take place at the Vascular Center of Rijnstate Hospital. A venous cannula will be inserted to enable contrast administration. Ultrasound data will be collected at the caudal renal artery, infrarenal neck, aneurysm sac and both iliac arteries.
4D flow MRI
A 4D phase-contrast magnetic resonance imaging (4D flow MRI) scan of the abdominal aorta will be obtained 6 to 8 weeks before and 6 to 8 weeks after endovascular aneurysm repair.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
EchoPIV
All patients will undergo an echoPIV measurement 6 to 8 weeks before and 6 to 8 weeks after endovascular aneurysm repair. These measurements will take place at the Vascular Center of Rijnstate Hospital. A venous cannula will be inserted to enable contrast administration. Ultrasound data will be collected at the caudal renal artery, infrarenal neck, aneurysm sac and both iliac arteries.
4D flow MRI
A 4D phase-contrast magnetic resonance imaging (4D flow MRI) scan of the abdominal aorta will be obtained 6 to 8 weeks before and 6 to 8 weeks after endovascular aneurysm repair.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BMI ≤ 30 kg/m2
* Infrarenal AAA
* Scheduled for elective EVAR with the Endurant II stent graft
* Informed consent form understood and signed, and agrees to all visits
Exclusion Criteria
* Right-to-left cardiac shunt
* Severe pulmonary hypertension (pulmonary artery pressure \> 90mmHg)
* Uncontrolled systemic hypertension
* Severe pulmonary disease (e.g. COPD GOLD 3 or 4, adult respiratory distress syndrome)
* Clinically unstable cardiac disease (recent, \< 3 months, or ongoing myocardial infarction, unstable angina at rest, recent percutaneous coronary intervention, clinically worsening cardiac symptoms, severe cardiac arrhythmia's, endocarditis, etc.)
* Prosthetic valves
* Loss of renal function (GFR \< 31 ml/min), end-stage renal disease
* End-stage liver disease
* Sepsis
* Hypercoagulable status, recent (\< 3 months) thrombosis
* Congestive heart failure (class III or IV)
* Pregnancy
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Twente
OTHER
Rijnstate Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Rijnstate Hospital
Arnhem, , Netherlands
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2021-1917
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.